About UCB, Inc.
At UCB, everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” We have a passionate, long-term commitment to discovering and developing innovative medicines that transform the lives of people living with severe diseases. We do that by connecting with patients and their families around the world living with the physical and social burdens of severe disease. Those connections offer new perspectives, drive innovation, and offer the hope of a new generation of therapies that are helping to transform lives.
With a team of approximately 7,500 employees and operations in more than 40 countries, we are a global biopharmaceutical company investing more than a quarter of our revenue in cutting-edge scientific research to meet unmet patient needs. Global headquarters are in Brussels, Belgium, with U.S. headquarters in Atlanta, Georgia. Additional U.S. UCB sites include global clinical development at our Research Triangle Park, North Carolina campus (UCB Biosciences, Inc.), and research supporting UCB’s pipeline in Cambridge, Massachusetts (UCB Research, Inc.).
230 articles with UCB, Inc.
UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases
UCB and Ra Pharmaceuticals Inc. announced their entry into a merger agreement pursuant for which UCB will acquire Ra Pharma.
UCB indicates the deal is part of its strategic growth plan, dubbed the “Accelerate and Expand” phase since 2019.
Samsung BioLogics and UCB have agreed to an additional drug substance manufacturing deal under which SBL will also produce UCB's anti-tau candidate to treat progressive supranuclear palsy, pending regulatory approvals.
UCB Half Year Report 2019: UCB's Strong Performance Enables Continued Investment Into Future Growth Drivers
The strong financial performance in the first six months 2019 enables us as planned to accelerate our investments into future growth drivers
UCB's Key Pipeline Molecule Bimekizumab Demonstrated Improved Outcomes for Ankylosing Spondylitis Patients
UCB announced new Phase 2b data on the company's key pipeline molecule, bimekizumab, that showed improvements in a range of important health-related domains and general well-being for patients with active ankylosing spondylitis.ii Results from this study, which evaluated multiple treatment doses, were shared for the first time today at the Annual European Congress of Rheumatology, in Madrid.
UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.
UCB announced that the U.S. Food and Drug Administration has approved a New Drug Application for the company's newest anti-epileptic drug NAYZILAM® nasal spray CIV, a benzodiazepine indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older.
NAYZILAM was approved to treat frequent seizure cluster episodes in epilepsy patients.
The agency approved Evenity on the basis of two Phase III clinical trials. The drug had been rejected in 2017 over safety concerns.
FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
One in Two Women in the United States Will Suffer a Fracture in Her Lifetime Due to Osteoporosis
CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis
Patients living with non-radiographic axial spondyloarthritis, an often undiagnosed, chronic, painful and debilitating disease, now have an approved, clinically validated treatment
Arthritis & Rheumatology Publishes the First Randomized Placebo-Controlled Study Over 52 Weeks in Non-Radiographic Axial Spondyloarthritis Showing Positive Results for CIMZIA® (certolizumab pegol)
Results from C-AXSPAND, the first 52-week placebo-controlled study in adult patients with non-radiographic axial spondyloarthritis (nr-axSpA), demonstrated the potential impact of CIMZIA® (certolizumab pegol) when added to common background medications
Late breaking presentation of the Phase 2b long-term findings on the investigational molecule, bimekizumab, demonstrates complete or almost complete skin clearance in moderate-to-severe plaque psoriasis
UCB Full Year Report 2018: 2018 Marks the Fifth Consecutive Year of Profitable Growth, Intensifying Investment in UCB's Strong Pipeline
Revenue reached € 4.6 billion: +2%, +5% CER1; net sales increased to € 4.4 billion: +5%, +8% CER, driven by core products (+6%, +10% CER)
Sanofi, UCB, McKesson Ventures, and Horizon Health Services Endorse Aetion's Vision for Real-World Evidence
This follows a 2017 rejection by the agency, requesting more data. As Jefferies analyst Michael Yee wrote in a note to clients, Amgen is “back in the game.”
Amgen And UCB Announce FDA Advisory Committee Meeting To Review EVENITY™ (romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
Amgen and UCB today announced the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) will review data supporting the Biologics License Application (BLA) for EVENITYTM (romosozumab) for the treatment of osteoporosis in postmenopausal women at high risk for fracture at a meeting on Jan. 16, 2019.
Patient-centric drug delivery important for treatment adherence, commercial success
- Revenue reached € 3.4 billion (+3%; +6% CER)
Bimekizumab Showed Sustained Improvements in Both Joint and Skin Outcomes for Psoriatic Arthritis Patients
UCB, a global biopharmaceutical company, presented long-term data for the first time from BE ACTIVE, showing that response rates across musculoskeletal and skin manifestations with bimekizumab continued to increase in the dose-blind study period after Week 12, through Week 24, and were sustained to Week 48 in psoriatic arthritis (PsA) patients.
However, because the trial did show some efficacy and met other secondary endpoints, the companies are continuing to analyze the data and decide on their next moves.